Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00

Elanco Animal Health (NYSE:ELAN) had its price objective upped by UBS Group from $27.00 to $30.00 in a report published on Thursday,MarketScreener reports. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, November 19th. Morgan Stanley upped their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 18th. Barclays initiated coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.44.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $24.05 on Thursday. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $25.29. The firm has a fifty day simple moving average of $23.02 and a two-hundred day simple moving average of $20.35. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $11.95 billion, a PE ratio of 400.90, a price-to-earnings-growth ratio of 3.38 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 22,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the acquisition, the chief executive officer owned 167,000 shares in the company, valued at $3,632,250. This represents a 15.17% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev A. Modi bought 4,500 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average price of $21.33 per share, with a total value of $95,985.00. Following the completion of the transaction, the insider directly owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. New York State Teachers Retirement System raised its stake in Elanco Animal Health by 6.5% during the 4th quarter. New York State Teachers Retirement System now owns 291,055 shares of the company’s stock worth $6,587,000 after acquiring an additional 17,794 shares during the period. State of New Jersey Common Pension Fund D boosted its position in shares of Elanco Animal Health by 2.1% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 180,820 shares of the company’s stock worth $4,092,000 after purchasing an additional 3,783 shares during the period. Certuity LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth $232,000. Torren Management LLC bought a new stake in shares of Elanco Animal Health during the 4th quarter valued at $46,000. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Elanco Animal Health by 36.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 97,803 shares of the company’s stock valued at $2,213,000 after buying an additional 26,129 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.